LAMA5

Across TCGA pan-cancer cohorts, LAMA5 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated LAMA5 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher LAMA5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LAMA5 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUSC show a favorable association.

THYM, STAD, and LIHC are the cancer types where LAMA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	DFS	Median	All	0.142	0.878	<.001	48	view →
STAD	OS	Median	IV	0.056	0.510	<.001	15	view →
LIHC	DFS	Median	All	0.179	0.553	<.001	15	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	OS	Median	All	0.937	0.864	.023	7	view →
ESCA	DFS	Median	III,IV	0.149	0.454	.002	6	view →
BRCA	DFS	Median	II,III,IV	0.802	0.943	.017	4	view →
LUSC	DFS	Median	All	0.846	0.651	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

LAMA5–THYM (DFS)

Open the THYM breakdown →